Key facts
- It has raised $23.3M across 1 recorded rounds; the latest was Seed Round ($272K) in Dec 2021.
- Notable investors include Canadian Technology Accelerator, HATCH Venture Builder, VGH and UBC Hospital Foundation.
- Vesalius Cardiovascular has filed 5 Form Ds with the SEC since 2022, most recently Aug 2025 ($38K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Vesalius Cardiovascular
Funding rounds
1 roundsAbout Vesalius Cardiovascular
Developer of a transfemoral mitral valve repair device designed for degenerative mitral regurgitation of heart valve disease. The company's device is based on current surgical techniques of chordal replacement and annuloplasty, and it can treat any diseased area of the valve and covers the full range of valve sizes, enabling physicians to get a device that is adaptable and deployment-reversible.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2016
- Employees
- 12
- Website
- vesaliuscardio.com/
- Ownership
- Privately Held (backing)
Vesalius Cardiovascular doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vesalius Cardiovascular shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vesalius Cardiovascular in its N-PORT filings yet. We sweep new filings monthly.